
    
      This study includes two parts: Part A

      Subjects will be admitted to the clinical research unit on Day -1 and remain confined to the
      unit until post dosing discharge criteria are met up to a maximum of 10 days. On Day 1,
      subjects will receive a single oral dose of 14C-labeled OSI-906.

      Part B (optional)

      Once the subject has completed part A, the subject may elect to continue participation in
      Part B. Subjects will receive OSI-906 (non-radiolabeled) twice daily by mouth. Subjects will
      be seen for scheduled visits every 7 days for the first 36 days and then every 21 days.
    
  